Balyasny Asset Management’s Checkpoint Therapeutics CKPT Stock Holding History

Balyasny Asset Management’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-81,542	Closed	-$329K	–	2884
2025 Q1	$329K	Buy	81,542 +61,321	+303%	+$204K	﹤0.01%	2417
2024 Q4	$64.7K	Buy	+20,221	New	+$68.6K	﹤0.01%	2628

Balyasny Asset Management's CKPT Position: Q2 2025 in Review

Balyasny Asset Management sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 81,542 shares — an estimated $329K sold.

Balyasny Asset Management first reported a position in CKPT in Q4 2024 and held it in 2 quarters. The position peaked at $329K in Q1 2025. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.

Balyasny Asset Management reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
Balyasny Asset Management sold 81,542 Checkpoint Therapeutics shares in Q2 2025, an estimated $329K.
Balyasny Asset Management first reported a position in Checkpoint Therapeutics in Q4 2024 and held it in 2 quarters.
Balyasny Asset Management's Checkpoint Therapeutics position peaked at $329K in Q1 2025.
0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.